专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

WO2014159662A1 METHOD FOR ISOLATION AND PURIFICATION OF MICROVESICLES FROM CELL CULTURE SUPERNATANTS AND BIOLOGICAL FLUIDS 审中-公开
标题翻译：从细胞培养物和生物流体中分离和纯化微生物的方法
公开(公告)号：WO2014159662A1
公开(公告)日：2014-10-02
申请号：PCT/US2014/024629
申请日：2014-03-12
申请人： UNIVERSITY OF MIAMI
发明人： BADIAVAS, Evangelos V. , SHABBIR, Arsalan Q. , DAVIS, Stephen C.
IPC分类号： G01N1/34 , G01N1/40 , C12N15/88 , A61K9/127 , A61P17/00 , A61P25/00 , A61P37/00
CPC分类号： A61K35/28 , A61K8/981 , A61K8/983 , A61K35/12 , A61K35/16 , A61K35/22 , A61K2800/74 , A61K2800/86 , A61Q19/00 , A61Q19/08
摘要： The present invention relates to the fields of medicine, cell biology, molecular biology and genetics. In particular, the present invention provides methods to isolate and purify microvesicles from cell culture supernatants and biological fluids. The present invention also provides pharmaceutical compositions of microvesicles to promote or enhance wound healing, stimulate tissue regeneration, remodel scarred tissue, modulate immune reactions, alter neoplastic cell growth and/or mobility, or alter normal cell growth and/or mobility. The present invention also provides compositions of microvesicles to be used as diagnostic reagents, and methods to prepare the compositions of microvesicles.
摘要翻译：本发明涉及医学，细胞生物学，分子生物学和遗传学领域。特别地，本发明提供从细胞培养上清液和生物流体中分离和纯化微泡的方法。本发明还提供了用于促进或增强伤口愈合，刺激组织再生，改造瘢痕组织，调节免疫反应，改变肿瘤细胞生长和/或移动性或改变正常细胞生长和/或移动性的微泡的药物组合物。本发明还提供了用作诊断试剂的微泡组合物，以及制备微泡组合物的方法。

62. 发明申请

WO2014149953A1 METHODS FOR PREPARING TISSUE IMPLANTS 审中-公开
标题翻译：用于制备组织植入物的方法
公开(公告)号：WO2014149953A1
公开(公告)日：2014-09-25
申请号：PCT/US2014/021625
申请日：2014-03-07
申请人： CRYOLIFE, INC.
发明人： HAMBY, Joseph , GOLDSTEIN, Steven , ROHDE, Valerie
IPC分类号： A61L27/36
CPC分类号： A61K35/12 , A61L27/362 , A61L27/3687 , A61L2430/40
摘要： A method is provided for preparing a biological tissue for implantation. The method includes providing a biological tissue from a human or animal donor, treating the biological tissue with an antiviral treatment formulation, lysing the biological tissue, decellularizing the biological tissue with a decellularization treatment formulation, and decontaminating the biological tissue with an alkaline alcohol solution. The antiviral treatment formulation may include a solution of peracetic acid and an alcohol, wherein the peracetic acid is present in the antiviral treatment formulation at a concentration from about 0.03% to about 1.2% (v/v). The decellularization solution may include a solution of a polar aprotic solvent, such as dimethyl sulfoxide, benzyl alcohol and ethanol.
摘要翻译：提供了一种用于制备用于植入的生物组织的方法。该方法包括从人或动物供体提供生物组织，用抗病毒处理制剂处理生物组织，裂解生物组织，用脱细胞处理制剂脱细胞化生物组织，并用碱性醇溶液去除生物组织。抗病毒治疗制剂可以包括过乙酸和醇的溶液，其中过氧乙酸以约0.03％至约1.2％（v / v）的浓度存在于抗病毒治疗制剂中。脱细胞溶液可以包括极性非质子溶剂如二甲基亚砜，苄醇和乙醇的溶液。

63. 发明申请

WO2014145205A2 METHODS AND COMPOSITIONS OF P27KIP1 TRANSCRIPTION MODULATORS 审中-公开
标题翻译： P27KIP1转录调节剂的方法和组成
公开(公告)号：WO2014145205A2
公开(公告)日：2014-09-18
申请号：PCT/US2014/029927
申请日：2014-03-15
申请人： ST. JUDE CHILDREN'S RESEARCH HOSPITAL
发明人： ZUO, Jian , CHEN, Taosheng , WALTERS, Brandon , KUO, Bryan , WALTERS, Bradley
IPC分类号： A61K31/519
CPC分类号： A61K38/1703 , A61K9/0046 , A61K31/05 , A61K31/222 , A61K31/44 , A61K31/4418 , A61K31/55 , A61K35/12 , A61K38/17 , A61K45/06 , C12N5/0602 , C12N5/062
摘要： In one aspect, the invention relates to pharmaceutical compositions comprising agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof; and agents that inhibit the expression of p27 Kipl , or pharmaceutically acceptable salts, solvates, or polymorphs thereof, which are useful for inducing the formation of cochlear hair cells; and methods of treating hearing impairments or disorders using the compositions. In one aspect, the invention relates to pharmaceutical compositions comprising β-catenin; and agents that activate the expression of Atoh1, or pharmaceutically acceptable salts, solvates, or polymorphs thereof. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
摘要翻译：一方面，本发明涉及包含活化Atoh1表达的试剂或其药学上可接受的盐，溶剂化物或多晶型物的药物组合物; 以及可用于诱导耳蜗毛细胞形成的p27Kipl或其药学上可接受的盐，溶剂化物或多晶型物的表达的药剂; 以及使用该组合物治疗听力障碍或障碍的方法。一方面，本发明涉及包含β-联蛋白的药物组合物; 以及激活Atoh1表达的药剂，或其药学上可接受的盐，溶剂化物或多晶型物。该摘要旨在作为用于在特定技术中进行搜索的扫描工具，而不意在限制本发明。

64. 发明申请

WO2014143737A1 CELL CULTURE CASSETTES AND INCUBATOR 审中-公开
标题翻译：细胞培养箱和孵化器
公开(公告)号：WO2014143737A1
公开(公告)日：2014-09-18
申请号：PCT/US2014/027821
申请日：2014-03-14
申请人： SAGE SCIENCE, INC.
发明人： MAGNANT, Gary, Paul
IPC分类号： C12M3/00 , C12N5/02 , A61K35/12 , C12Q1/02
CPC分类号： C12M23/42 , A61K35/12 , C12M23/34 , C12M25/00 , C12M41/12 , C12M41/26 , C12M41/32 , C12M41/34 , C12M41/36
摘要： The invention relates to cassettes for culturing cells. The invention also relates to analytical and preparative incubators for housing the cassettes. The invention also relates to methods of using the cassettes, for example, to culture cells wherein the processes of feeding and passaging cells are automated.
摘要翻译：本发明涉及培养细胞的盒。本发明还涉及用于容纳盒的分析和制备培养箱。本发明还涉及使用盒的方法，例如培养细胞，其中进食和传代细胞的过程是自动化的。

65. 发明申请

WO2014133541A2 METHOD AND SYSTEM FOR TREATMENT OF CARDIOVASCULAR DISORDERS 审中-公开
标题翻译：用于治疗心血管疾病的方法和系统
公开(公告)号：WO2014133541A2
公开(公告)日：2014-09-04
申请号：PCT/US2013/028579
申请日：2013-03-01
申请人： CORMATRIX CARDIOVASCULAR, INC.
发明人： MATHENY, Robert, G.
IPC分类号： A61K38/18
CPC分类号： A61K35/12 , A61K31/138 , A61K31/166 , A61K31/167 , A61K31/22 , A61K31/277 , A61K31/366 , A61K31/40 , A61K31/405 , A61K31/4166 , A61K31/4418 , A61K31/505 , A61K31/5377 , A61K35/22 , A61K35/30 , A61K35/34 , A61K35/36 , A61K35/38 , A61K35/39 , A61K35/42 , A61K35/50 , A61K38/18 , A61K38/1808 , A61K38/1825 , A61K38/1833 , A61K38/1841 , A61K38/185 , A61K38/1858 , A61K38/1866 , A61K38/191 , A61K2300/00
摘要： Methods for treating a cardiovascular disorder comprising concomitant administration of one or more extracellular matrix (ECM) based compositions directly to damaged or diseased cardiovascular tissue associated with the cardiovascular disorder, and provision of ventricular assistance. In a preferred embodiment, the ECM based compositions include an ECM material derived from a mammalian source.
摘要翻译：用于治疗心血管疾病的方法包括将一种或多种基于细胞外基质（ECM）的组合物直接施用于与心血管疾病相关的受损或患病的心血管组织并提供心室辅助。在优选的实施方案中，基于ECM的组合物包括衍生自哺乳动物来源的ECM材料。

66. 发明申请

WO2014110269A1 DECELLULARIZED BIOMATERIAL FORM NON-MAMMALIAN TISSUE 审中-公开
标题翻译：细菌生物体形式非马姆利亚组织
公开(公告)号：WO2014110269A1
公开(公告)日：2014-07-17
申请号：PCT/US2014/010890
申请日：2014-01-09
申请人： EARLY, Ryanne
发明人： EARLY, Ryanne
IPC分类号： A61K35/56 , A61K9/10 , A61K9/14 , A61F2/00 , A61L27/36
CPC分类号： A61L27/3687 , A61K9/70 , A61K35/12 , A61K35/65 , A61K38/1703 , A61L27/3604 , A61L27/362 , A61L27/3625 , A61L27/3633 , A61L27/3691 , A61L27/38 , A61L27/52 , A61L27/54 , A61L27/58 , A61L27/60 , A61L2300/252 , A61L2300/412 , A61L2300/604 , A61L2300/606 , A61L2300/64 , A61L2430/34 , A61L2430/40 , C12N5/0625 , C12N2533/90 , C12N2533/92
摘要： The growth factor profile, connective tissue matrix constituents, and immunoprivileged status of urodele extracellular matrix (ECM) and accompanying cutaneous tissue, plus the presence of antimicrobial peptides there, render urodele-derived tissue an ideal source for biological scaffolds for xenotransplantation. In particular, a biological scaffold biomaterial can be obtained by a process that entails (A) obtaining a tissue sample from a urodele, where the tissue comprises ECM, inclusive of the basement membrane, and (B) subjecting the tissue sample to a decellularization process that maintains the structural and functional integrity of the extracellular matrix, by virtue of retaining its fibrous and non-fibrous proteins, glycoaminoglycans (GAGs) and proteoglycans, while removing sufficient cellular components of the sample to reduce or eliminate antigenicity and immunogenicity for xenograft purposes. The resultant urodele-derived biomaterial can be used to enhance restoration of skin homeostasis, to reduce the severity, duration and associated damage caused by post-surgical inflammation, and to promote progression of natural healing and regeneration processes. In addition, the biomaterial promotes the formation of remodeled tissue that is comparable in quality, function, and compliance to undamaged human tissue.
摘要翻译： Urodele细胞外基质（ECM）和伴随皮肤组织的生长因子分布，结缔组织基质成分和免疫缺陷状态加上抗微生物肽的存在使得urodele衍生组织成为用于异种移植的生物支架的理想来源。特别地，生物支架生物材料可以通过以下方法获得：（A）从尿布获得组织样品，其中组织包括ECM，包括基底膜，和（B）使组织样品经脱细胞化过程通过保留其纤维和非纤维蛋白，糖胺聚糖（GAG）和蛋白多糖来维持细胞外基质的结构和功能完整性，同时去除样品的足够的细胞组分以减少或消除异种移植物目的的抗原性和免疫原性。所得到的urodele衍生的生物材料可用于增强皮肤稳态的恢复，以减少手术后炎症引起的严重程度，持续时间和相关的损伤，并促进自然愈合和再生过程的进展。此外，生物材料促进了改性组织的形成，其质量，功能和对未损伤的人体组织的依从性。

67. 发明申请

WO2014105913A1 CELLULAR COMPOSITIONS FOR TISSUE ENGINEERING 审中-公开
标题翻译：用于组织工程的细胞组合物
公开(公告)号：WO2014105913A1
公开(公告)日：2014-07-03
申请号：PCT/US2013/077715
申请日：2013-12-24
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人： BYRNE, James, A. , WANG, Jeffrey C.
IPC分类号： C12N5/18 , C12N5/077 , A61K35/12 , A61L27/38 , A61P19/08 , A61K38/18
CPC分类号： A61K35/32 , A61K35/12 , A61K35/33 , A61K35/35 , A61K38/1875 , A61K38/39 , A61L24/0005 , A61L24/102 , A61L27/24 , A61L27/3633 , A61L27/3804 , A61L2300/64 , A61L2400/06 , A61L2430/02 , A61L2430/38 , C12N5/0656 , C12N2510/00 , C12N2511/00 , C12N2533/54 , A61K2300/00
摘要： Cell compositions for tissue engineering are provided which contain a population of autologous, minimally passaged dermal fibroblasts in combination with a tissue engineering matrix or scaffold, or material forming a matrix or scaffold. In one embodiment, the population of fibroblasts is genetically engineered to secrete a therapeutic protein in an amount effective to induce tissue growth or tissue repair when the cell composition is transplanted into a subject in need thereof. For example, the therapeutic protein can be a bone morphogenic protein when the tissue to be treated is bone tissue. A preferred bone morphogenic protein is BMP-2.
摘要翻译：提供用于组织工程的细胞组合物，其含有与组织工程基质或支架组合的自体，最小传代的真皮成纤维细胞群体或形成基质或支架的材料。在一个实施方案中，当将细胞组合物移植到有需要的受试者中时，成纤维细胞群被遗传工程化以分泌有效诱导组织生长或组织修复的量的治疗性蛋白质。例如，当待治疗的组织是骨组织时，治疗性蛋白质可以是骨形态发生蛋白质。优选的骨形态发生蛋白是BMP-2。

68. 发明申请

WO2014102799A1 CD11blow MACROPHAGES AND CONDITIONED MEDIA THEREOF FOR TREATING CANCER AND/OR FIBROSIS 审中-公开
标题翻译： CD11blow用于治疗癌症和/或纤维化的宏观和有条件的媒体
公开(公告)号：WO2014102799A1
公开(公告)日：2014-07-03
申请号：PCT/IL2013/051084
申请日：2013-12-30
申请人： CARMEL-HAIFA UNIVERSITY ECONOMIC CORPORATION LTD
发明人： BARKAN, Dalit , GILON, Odelya , ARIEL, Amiram , SCHIF-ZUCK, Sagie
IPC分类号： A61K35/12 , C12N5/0786
CPC分类号： A61K35/15 , A61K35/12 , A61K45/06 , C12N5/0645 , C12N5/0656 , C12N2500/70 , C12N2501/15 , C12N2501/58 , C12N2502/00 , C12N2502/1157 , C12N2506/11 , C12N2506/115 , C12N2506/1307
摘要： A conditioned medium of CD11b low macrophages and methods for preparing it are provided. Pharmaceutical compositions comprising the CD11b low macrophages conditioned medium or a culture of CD11b low macrophages and their use in the treatment of cancer or fibrosis are also provided.
摘要翻译：提供了CD11blow巨噬细胞的条件培养基及其制备方法。还提供了包含CD11blow巨噬细胞条件培养基或CD11blow巨噬细胞培养物的药物组合物及其在治疗癌症或纤维化中的用途。

69. 发明申请

WO2014089668A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF BRAIN CANCERS 审中-公开
标题翻译：用于治疗脑癌的组合物和方法
公开(公告)号：WO2014089668A1
公开(公告)日：2014-06-19
申请号：PCT/CA2012/050893
申请日：2012-12-12
申请人： CHILDREN'S HOSPITAL OF EASTERN ONTARIO RESEARCH INSTITUTE INC. , OTTAWA HOSPITAL RESEARCH INSTITUTE
发明人： STOJDL, David , BELL, John, Cameron
IPC分类号： C12N7/01 , A61K35/12 , A61K35/76 , A61P35/00 , C07K14/08 , C07K14/145 , C12N15/40 , C12N15/47 , C12N15/62 , C12N15/86
CPC分类号： C07K14/005 , A61K9/0019 , A61K9/0085 , A61K35/12 , A61K35/766 , C12N7/00 , C12N2760/14033 , C12N2760/20232 , C12N2760/20233 , C12N2760/20262 , C12N2810/6072 , C12N2810/6081
摘要： Described herein is an isolated viral particle having a genome that includes open reading frames that encode: Maraba proteins N, P, and L, or variants thereof; as well as Maraba protein M or protein delta 51M, or variants thereof; and a Bahia Grande G protein, a LCMV G protein, or an Ebola G protein. Maraba protein N may have a sequence which includes SEQ ID NO: 1. Maraba protein P may have a sequence which includes SEQ ID NO: 2. Maraba protein L may have a sequence which includes SEQ ID NO: 3. Maraba proteins M and delta 1M may have sequence which include SEQ ID NO: 4 and 5, respectively. Bahia Grande G protein may have a sequence which includes SEQ ID NO: 6. LCMV G protein may have a sequence which includes SEQ ID NO: 7. Ebola G protein may have a sequence which includes SEQ ID NO: 8.
摘要翻译：本文描述的是具有包含编码Maraba蛋白N，P和L或其变体的开放阅读框的基因组的分离的病毒颗粒; 以及Maraba蛋白M或蛋白质δ51M，或其变体; 和巴伊亚格兰德G蛋白，LCMV G蛋白或埃博拉G蛋白。 Maraba蛋白N可以具有包含SEQ ID NO：1的序列.Maraba蛋白P可以具有包含SEQ ID NO：2的序列.Maraba蛋白L可以具有包含SEQ ID NO：3的序列.Maraba蛋白M和δ 1M可以分别具有包括SEQ ID NO：4和5的序列。巴伊亚格兰德G蛋白可以具有包含SEQ ID NO：6的序列.LCMV G蛋白可以具有包含SEQ ID NO：7的序列。埃博拉G蛋白可以具有包含SEQ ID NO：8的序列。

70. 发明申请

WO2014089440A1 TREATING ORAL LESIONS USING PLACENTAL EXTRACELLULAR MATRIX 审中-公开
标题翻译：使用平面细胞基质处理口腔溃疡
公开(公告)号：WO2014089440A1
公开(公告)日：2014-06-12
申请号：PCT/US2013/073593
申请日：2013-12-06
申请人： ANTHROGENESIS CORPORATION
发明人： HARIRI, Robert, J. , GURNEY, Jodi, P. , BHATIA, Mohit, B. , HOFGARTNER, Wolfgang
IPC分类号： A61K35/12 , A61P17/02 , C07K14/78
CPC分类号： A61K35/50 , A61K35/12
摘要： Provided herein are uses of compositions comprising extracellular matrix (ECM) and compositions comprising ECM components in the treatment of non-dental oral lesions.
摘要翻译：本文提供包含细胞外基质（ECM）的组合物和包含ECM组分的组合物在治疗非牙科口腔损伤中的用途。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式